FDA Updates on Compounded GLP-1 Medications

The FDA has been closely monitoring the compounded GLP-1 medication market as demand has exploded. In early 2026, the agency issued updated guidance clarifying the rules for 503A and 503B compounding pharmacies producing semaglutide and tirzepatide. Here's what patients need to know.

The key takeaway is that compounded GLP-1 medications remain legal and available when produced by properly licensed pharmacies during a drug shortage. The FDA maintains a shortage list, and as long as semaglutide or tirzepatide appear on it, compounding pharmacies can produce these medications. However, the FDA has cracked down on unlicensed operators and those making false claims about their products. Patients should verify that their provider works with a 503B-registered outsourcing facility or a state-licensed 503A pharmacy.

What does this mean for you? If you're currently using a compounded GLP-1 from a reputable provider, your treatment should continue uninterrupted. Look for providers that are transparent about their pharmacy partners and hold certifications like LegitScript verification. On our rankings, we flag providers that meet these safety standards. If you have concerns about your current provider's legitimacy, check the FDA's database of registered outsourcing facilities or consult our provider comparison tool to find a verified alternative.